Hemogenyx Pharmaceuticals PLC (HEMO) - Cash Flow Conversion Efficiency

Latest as of December 2024: -2.090x

Based on the latest financial reports, Hemogenyx Pharmaceuticals PLC (HEMO) has a cash flow conversion efficiency ratio of -2.090x as of December 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-1.78 Million ≈ $-216.99 USD) by net assets (GBX853.49K ≈ $103.85 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See HEMO defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Hemogenyx Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Hemogenyx Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Hemogenyx Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hemogenyx Pharmaceuticals PLC ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
STV Group plc LSE:STVG	-0.602x
Sacks Parente Golf, Inc. Common Stock NASDAQ:SPGC	-0.252x
Cora Gold Limited LSE:CORA	-0.013x
Revolution Beauty Group PLC LSE:REVB	0.074x
Steppe Cement LSE:STCM	0.038x
J Smart Co Contractors PLC LSE:SMJ	0.039x
CML Microsystems Plc LSE:CML	0.030x
Reliance Industries Limited IL:RIGD	N/A

Annual Cash Flow Conversion Efficiency for Hemogenyx Pharmaceuticals PLC (2015–2024)

The table below shows the annual cash flow conversion efficiency of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Hemogenyx Pharmaceuticals PLC market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	GBX853.49K ≈ $103.85	GBX-4.12 Million ≈ $-500.91	-4.824x	-119.71%
2023-12-31	GBX2.78 Million ≈ $338.37	GBX-6.11 Million ≈ $-742.87	-2.195x	-144.66%
2022-12-31	GBX3.24 Million ≈ $394.64	GBX-2.91 Million ≈ $-354.14	-0.897x	-178.97%
2021-12-31	GBX8.17 Million ≈ $993.76	GBX-2.63 Million ≈ $-319.67	-0.322x	+84.34%
2020-12-31	GBX875.68K ≈ $106.55	GBX-1.80 Million ≈ $-218.81	-2.054x	-159.74%
2019-12-31	GBX-349.04K ≈ $-42.47	GBX-1.20 Million ≈ $-145.99	3.438x	+343.75%
2018-12-31	GBX959.17K ≈ $116.70	GBX-1.35 Million ≈ $-164.59	-1.410x	-563.74%
2017-12-31	GBX2.13 Million ≈ $259.39	GBX-452.98K ≈ $-55.11	-0.212x	+30.96%
2016-12-31	GBX903.71K ≈ $109.96	GBX-278.15K ≈ $-33.84	-0.308x	-30148.52%
2015-12-31	GBX77.82K ≈ $9.47	GBX79.71 ≈ $0.01	0.001x	--

About Hemogenyx Pharmaceuticals PLC

LSE:HEMO UK Biotechnology

Market Cap

$534.24K

GBX4.39 Billion GBX

Market Cap Rank

#30823 Global

#908 in UK

Share Price

GBX819.00

Change (1 day)

+2.76%

52-Week Range

GBX130.00 - GBX1545.00

All Time High

GBX1545.00